Novartis’ CAR-T shows durable response in lymphoma patients – PharmaTimes
PharmaTimes |
Novartis' CAR–T shows durable response in lymphoma patients
PharmaTimes Novartis' closely-watched CTL019 has elicited a strong response in cancer patients taking the experimental CAR–T cell therapy in a mid-stage trial. Findings from an interim analysis of the multicentre Phase II JULIET study show a three-month overall … |
